Tempus Wealth Planning LLC Increases Stock Position in Haleon plc (NYSE:HLN)

Tempus Wealth Planning LLC raised its position in shares of Haleon plc (NYSE:HLN) by 4.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 54,813 shares of the company’s stock after buying an additional 2,136 shares during the quarter. Tempus Wealth Planning LLC’s holdings in Haleon were worth $465,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HLN. Wellington Management Group LLP raised its position in shares of Haleon by 164.6% in the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock worth $111,454,000 after purchasing an additional 8,423,475 shares during the last quarter. Cambiar Investors LLC purchased a new position in Haleon in the 4th quarter worth about $15,225,000. Goldman Sachs Group Inc. raised its position in Haleon by 19.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 4,813,997 shares of the company’s stock worth $39,619,000 after buying an additional 772,829 shares during the last quarter. Optiver Holding B.V. raised its position in Haleon by 223.0% in the 4th quarter. Optiver Holding B.V. now owns 1,008,565 shares of the company’s stock worth $8,260,000 after buying an additional 696,327 shares during the last quarter. Finally, Clearbridge Investments LLC raised its position in Haleon by 2.4% in the 4th quarter. Clearbridge Investments LLC now owns 26,581,902 shares of the company’s stock worth $218,769,000 after buying an additional 612,400 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on HLN. Berenberg Bank began coverage on Haleon in a research report on Wednesday, June 5th. They issued a “buy” rating for the company. Argus reissued a “buy” rating on shares of Haleon in a research report on Tuesday, March 26th. Finally, HSBC began coverage on Haleon in a research report on Wednesday, April 17th. They issued a “buy” rating for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Haleon has an average rating of “Moderate Buy”.

Haleon Stock Performance

Shares of Haleon stock traded up $0.13 during trading hours on Thursday, reaching $8.46. 1,761,770 shares of the stock traded hands, compared to its average volume of 3,326,346. The company has a 50 day moving average price of $8.41 and a 200 day moving average price of $8.35. The firm has a market capitalization of $38.63 billion, a price-to-earnings ratio of 28.18, a P/E/G ratio of 2.21 and a beta of 0.24. Haleon plc has a one year low of $7.70 and a one year high of $8.96. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.53.

Haleon (NYSE:HLN) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. The business had revenue of $3.70 billion during the quarter, compared to the consensus estimate of $3.71 billion. Haleon had a return on equity of 13.17% and a net margin of 9.68%. On average, equities research analysts expect that Haleon plc will post 0.46 earnings per share for the current fiscal year.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.